EU, method C preference [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2019-10-11 12:25 (1715 d 07:31 ago) – Posting: # 20683
Views: 5,748

Hi all,

I remember having heard EU regulators mention preference for method C out of consideration for the type I error. But I can't seem to find a presentation from anyone saying so. Do you know, do one of you experts have a link or a presentation by a regulator where this was stated?

Many thanks.

Pass or fail!
ElMaestro

Complete thread:

UA Flag
Activity
 Admin contact
23,059 posts in 4,841 threads, 1,664 registered users;
38 visitors (0 registered, 38 guests [including 7 identified bots]).
Forum time: 19:57 CEST (Europe/Vienna)

[…] an inappropriate study design is incapable of answering
a research question, no matter how careful the subsequent
methodology, conduct, analysis, and interpretation:
Flawless execution of a flawed design achieves nothing worthwhile.    J. Rick Turner

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5